1. Home
  2. NWN vs ADPT Comparison

NWN vs ADPT Comparison

Compare NWN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NWN

Northwest Natural Holding Company

HOLD

Current Price

$52.78

Market Cap

2.1B

Sector

Utilities

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$16.48

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NWN
ADPT
Founded
1859
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.5B
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
NWN
ADPT
Price
$52.78
$16.48
Analyst Decision
Buy
Strong Buy
Analyst Count
2
9
Target Price
$49.50
$17.78
AVG Volume (30 Days)
242.2K
1.6M
Earning Date
06-01-2026
05-05-2026
Dividend Yield
3.75%
N/A
EPS Growth
36.45
63.89
EPS
2.77
N/A
Revenue
$1,289,363,000.00
$276,976,000.00
Revenue This Year
$8.97
$3.98
Revenue Next Year
$4.27
$22.72
P/E Ratio
$18.97
N/A
Revenue Growth
11.83
54.77
52 Week Low
$38.94
$6.26
52 Week High
$53.66
$20.76

Technical Indicators

Market Signals
Indicator
NWN
ADPT
Relative Strength Index (RSI) 71.77 50.88
Support Level $45.72 $14.87
Resistance Level N/A $17.72
Average True Range (ATR) 1.24 0.76
MACD 0.29 0.09
Stochastic Oscillator 82.59 79.33

Price Performance

Historical Comparison
NWN
ADPT

About NWN Northwest Natural Holding Company

Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in one reportable business segment, which is NW Natural's local gas distribution business and is referred to as the NGD segment. The company generates its revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Share on Social Networks: